Clinical Insights on the Efficacy and Safety of Bispecific Antibodies in Multiple Myeloma

In this episode, experts offer clinical perspectives on the efficacy and safety of bispecific antibodies by highlighting real world findings and emerging trial data. Panelists discuss teclistamab outcomes in frail, trial-ineligible patients, noting response rates comparable to those observed in clinical studies and emphasizing that early response assessment within the first three months guides treatment continuation. Experts expand on safety considerations, explaining that cytokine release syndrome is generally low grade and that neurotoxicity is uncommon across BCMA- and GPRC5D-targeted bispecifics. They stress the importance of managing infections, which become a dominant risk after the initial step-up phase. The conversation moves to additional bispecifics, including linvoseltamab and talquetamab, with updates showing strong activity even in high-risk and heavily pretreated populations. Panelists also describe combination strategies with anti-CD38 antibodies and IMiDs to enhance T-cell function and deepen responses, underscoring the rapidly evolving therapeutic landscape.